Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Objective: To summarize evidence on the rates and drivers of progression from
normoglycemia to prediabetes and/or diabetes mellitus (hereafter “diabetes”) in antiretroviral …

Objective: To investigate HIV, its treatment, and hypertension as stroke risk factors in
Malawian adults. Methods: We performed a case-control study of 222 adults with acute …

Background Retention in care is an essential component of meeting the UNAIDS “90-90-90”
HIV treatment targets. In Khayelitsha township (population~ 500,000) in Cape Town, South …

Antiretroviral therapy has dramatically reduced mortality in human immunodeficiency virus
(HIV) infection. In 1988, the suggestion that the first antiretroviral drug, zidovudine, was the …

Objective. To review available literature on the prevalence, risk factors, pathophysiology,
and clinical outcomes of dysglycemia among people living with HIV (PLHIV) in sub‐Saharan …

Combination antiretroviral therapy (cART) dramatically changed the face of the HIV/AIDS
pandemic, making it one of the most prominent medical breakthroughs of the past 3 …

Although the underlying mechanisms driving human immunodeficiency virus (HIV)-mediated
cardiovascular diseases (CVD) onset and progression remain unclear, the role of chronic …

Background While dyslipidemia importantly contributes to increased cardiovascular disease
risk among patients on antiretroviral therapy (ART), data on lipid patterns among African …

Sensory peripheral neuropathy (PN) remains a common complication in HIV-positive
patients despite effective combination anti-retroviral therapy (ART). Data on PN on second …